Die Photodynamische Therapie (PDT) hat sich zunehmend als vielversprechende Methode zur Behandlung von verschiedenen malignen Neubildungen gezeigt. Die photodynamische Zerstörung der Tumore wird erreicht indem zunächst ein Photosensibilisator entweder lokal oder systemisch appliziert wird und im Anschluss an eine gewisse Inkubationszeit die Tumormasse mittels einer Lichtquelle mit einer spezifischen Wellenlänge durchleuchtet wird. Aufgrund der bevorzugten Anreicherung des Photosensibilisators in Tumorzellen, erlaubt diese Methode eine selektive Abtötung des malignen Tumors, während das umliegende Gewebe weitestgehend verschont wird. Diese Eigenschaften und Anforderungen machen die PDT, insbesondere in den Fällen, wo die chirurgische Enukleation als kurative Option erwogen wird, zu einer attraktiven Therapieoption in der Behandlung von Retinoblastomen (Rb). Die extreme Methode der Enukleation wird noch immer angewendet, wenn die Tumoren nicht ausreichend chemosensibel sind, oder wenn sich die Erkrankung aufgrund von unzureichendem Zugang zu medizinischer Versorgung bereits in einem fortgeschrittenen Stadium befindet. In dieser Studie haben wir zunächst In-Vitro-Untersuchungen mit dem neuen kationischen wasserlöslichen Photosensibilisator Tetrahydroporphyrin-Tetratosylat (THPTS) bezüglich seiner photodynamischen Wirkung auf WERI Rb-1 und Y79-Retinoblastomzellen durchgeführt. Dabei konnten wir zeigen, dass weder die Inkubation mit THPTS ohne anschließende Beleuchtung, noch die alleinige Beleuchtung zu einem signifikanten Effekt auf die Proliferation der Rb-Zellen führte. Die Kombination von THPTS mit anschließender Beleuchtung hingegen führte zu einem maximal zytotoxischen Effekt in den Tumorzellen. Darüber hinaus war die Phototoxizität in normalen Primärzellen des Pigmentepithels der Retina geringer, wodurch ein erhöhter phototoxischer Effekt von THPTS in Krebszellen gegenüber diesem normalen Zelltyp der Retina gezeigt werden konnte. Die vorliegenden Ergebnisse bilden eine ermutigende Grundlage für weiterführende in-vivo-Untersuchungen zum therapeutischen Potential dieses vielversprechenden Photosensibilisators mit der Aussicht auf eine potentiell kurative Therapie des Retinoblastoms unter Erhalt von Augapfel und Visus.

Although it is unclear which cellular factor(s) is responsible for the genetic instability associated with initiating and sustaining cell transformation, it is known that most, if not all, cancers have mutations that inactivate the Rb-mediated growth control pathway. We show here that acute inactivation of Rb by RNA interference or expression of the E7 viral oncoprotein from human papillomavirus (HPV), and the resultant deregulation of one E2F family member, E2F1, leads to DNA double strand break (DSB) accumulation. These DSBs occur independent of apoptosis induction, and activation of ATM, NBS1, p53, or MAD2, and generation of reactive oxygen species (ROS). Although ROS accumulation is associated with DSBs generated from the mis-expression of another nuclear oncoprotein, c-MYC, we find that E2F1 does not contribute to c-MYC associated DSBs, indicating that the DSBs associated with these oncoproteins arise through distinct pathways. However, we find that small changes in E2F1 levels by inhibition of c-MYC transactivated microRNAs known to limit E2F1 protein expression, lead to DSB accumulation. These results suggest that despite the DSBs arising by different mechanisms, c-MYC assists in the regulation of E2F1-associated DSBs. We also find elevated levels of E2F1-associated DSBs in Rb mutated cancer cell lines in the absence of an exogenous DSB stimulus. These basal, E2F1-associated DSBs are substantially lower in Rb wildtype cancer cell lines that have p16ink4 inactivated or express HPV E7. However, we show that we can manipulate DSB levels in these cancer cell lines by modulating Rb and E2F1 activity and suggest that these results may be extended to breast tumor organ culture. Thus, Rb status is key to regulating both the proliferation promoting functions associated with E2F and for preventing DNA damage accumulation if E2F1 becomes deregulated. Taken together, these data suggest that loss of Rb creates strong selective pressure, via DSB accumulation, for inactivating p53 mutations and that E2F1 might contribute to the genetic instability associated with transformation and tumorigenesis.

The proper maintenance of the pathways governing cell growth is critical to ensure cell survival and DNA fidelity. Much of our understanding of how the cell cycle is regulated comes from studies examining the relationship between DNA viruses and the mechanisms of cell proliferation control. There are numerous examples demonstrating that viruses can alter the host cell environment to their advantage. In particular, the small DNA tumor viruses, which include adenovirus, simian-virus 40 (SV-40), and human papillomavirus (HPV), can modulate the host cell cycle to facilitate viral DNA replication. Due to the fact that these viruses infect quiescent, non-cycling cells and lack the necessary enzymes and resources to replicate their DNA (e.g. DNA polymerase), the small DNA tumor viruses must activate the host cell replication machinery in order to expedite viral DNA replication. The capacity of these viruses to perturb normal cell proliferation control is dependent upon their oncogene products, which target p53 and members of the Retinoblastoma (RB) family of proteins and inactivate their respective functions. By targeting these key cell cycle regulatory proteins, the small DNA tumor viruses induce the infected host cells to enter S-phase and activate the components involved with host cell DNA synthesis thereby generating an environment that is conducive to viral DNA replication. In contrast, the larger, nuclear-replicating DNA viruses such as those from the family Herpesviridae, do not share the same stringent requirement as the small DNA viruses to induce the infected host cell to enter S-phase. The herpesviruses encode many of the components to stimulate nucleotide biosynthesis and the necessary factors to facilitate virus DNA replication including a viral DNA polymerase and other accessory factors. Additionally, many herpesviruses encode gene products that arrest the host cell cycle, in most instances, prior to the G1/S transition point. Inducing cells to growth arrest appears to be a prerequisite for the replication of most herpesviruses. However, in addition to encoding factors that inhibit the cell cycle, many herpesviruses encode proteins that can promote cell cycle progression in a manner similar to the small DNA tumor virus oncoproteins. By targeting members of the RB family and p53 protein, the herpesvirus proteins induce S-phase and activate S-phase associated factors that playa role in DNA replication. In this manner, the herpesviruses may promote an environment that is favorable for DNA replication. Consistent with the other herpesviruses, human cytomegalovirus (HCMV)induces human fibroblasts to growth arrest. However, in other cell types, virus infection causes cells to enter S-phase. In addition, HCMV replication requires several cellular factors that are present only during S-phase. Furthermore, HCMV induces the activation of S-phase-associated events as well as the increased expression of numerous S-phase genes following infection. HCMV encodes two immediate early (IE) gene products, IE1-72 and IE2-86, which can interact with members of the RB family of proteins. Additionally, the IE2-86 protein can bind to and inhibit p53 protein function. Given the functional resemblance between the HCMV IE proteins and the oncoproteins of the small DNA tumor viruses, we hypothesized that expression of the HCMV IE proteins could modulate cell cycle control. Specifically, we determined that expression of either IE1-72 or IE2-86 can induce quiescent cells to enter S-phase and delay cell cycle exit following serum withdrawal. Moreover, IE2-86 mediates this effect in the presence or absence of p53, whereas IE1-72 fails to do so in p53-expressing cells. Furthermore, both IE1-72 and IE2-86 induce p53 protein accumulation that is nuclear localized. Because IE1-72 fails to promote S-phase entry in cells expressing p53 and induces p53 protein levels, the mechanism by which IE1-72 alters p53 levels was examined. IE1-72 elevates p53 protein levels by inducing both p19ARF protein and an ATM-dependent phosphorylation of p53 at Ser15. IE1-72 also promotes p53 nuclear accumulation by abrogating p53 nuclear shuttling. As consequence of this IE1-72-mediated increase in p53 levels, p21 protein is induced leading to a p21-dependent growth arrest in cells expressing IE1-72. These findings demonstrate that the HCMV IE proteins can alter cell proliferation control and provide further support to the notion that HCMV, through the expression of its IE proteins, induces S-phase and factors associated with S-phase while blocking cell DNA synthesis, to possibly generate an environment that is suitable for viral DNA replication.

Les cellules différenciées peuvent être reprogrammées et adopter un destin cellulaire très différent. Connaître les acteurs et mécanismes qui contrôlent les processus de reprogrammation est un objectif scientifique fascinant qui éclairera notre compréhension du contrôle et du maintien de l'identité cellulaire. Notre laboratoire étudie le changement d'identité (ou transdifférenciation, TD) naturel d’une cellule épithéliale rectale (nommée Y) en motoneurone (nommé PDA) chez Caenorhabditis elegans. Dans les vers mutants pour le gène lin-15A (gène isolé dans un crible génétique du laboratoire), la cellule Y n'initie pas sa reprogrammation : Y demeure rectale. Cette protéine apparaît dans le noyau de Y juste avant le début de la TD de Y et joue un rôle clé dans l’initiation de ce processus. LIN-15A lie l’ADN et son domaine conservé en doigt de zinc (de type THAP-like) est essentiel pour initier la reprogrammation de Y. Nous nous sommes attachés à mieux comprendre le rôle de LIN-15A dans ce processus. L’inactivation de certains gènes (impliqués dans le maintien de l’identité cellulaire) permet de supprimer partiellement ou très fortement le défaut de reprogrammation de Y causé par la mutation lin-15A. Ces gènes appartiennent au groupe appelé synMuv B et ceux induisant la plus forte suppression du phénotype de lin-15A sont tous liés à la voie du rétinoblastome (RB). Dans la littérature, tous les mutants suppresseurs de défaut de PDA existant dans le mutant lin-15A présentaient une dérive de l’identité des cellules intestinales. Certains mutants de voies de réponse au jeûne chez le ver présentent également une perte du maintien de l’identité des cellules intestinales très similaire à celle induite par l’inactivation de certains gènes synMuv B. De façon très intéressante, nous avons pu observer que les vers mutants lin-15A présentent une pénétrance du défaut de PDA bien plus faible une fois privés de nourriture (au 1er stade larvaire ou au stade dauer). Certaines études laissent supposer que ces diapauses suite au jeûne entrainent une perte du maintien de l’identité cellulaire de cellules somatiques (et possiblement dans l’intestin), ce qui pourrait permettre à Y d’enclencher sa reprogrammation malgré l’absence de lin-15A, facteur clé à la levée du verrou pour initier la TD. En résumé, mes résultats ont montré que la transdifférenciation d'une cellule dépendait d'une clé moléculaire, LIN-15A, nécessaire pour lever un verrou de maintien de l'identité cellulaire dans la cellule qui va changer d'identité, et ce précisément juste avant la conversion cellulaire de Y en PDA. De façon plus générale, mes travaux ouvrent la possibilité que l'état physiologique et métabolique du ver influe sur le maintien de l'identité cellulaire. Sur le long terme, il conviendra alors de déterminer par quel biais cet état est perçu, dans quelles cellules, et comment cette information est relayée ou captée par la cellule Y, pour finalement influencer sa plasticité. / Differentiated cells can be reprogrammed to adopt a different cell identity. The discovery of factors and mechanisms controlling cellular reprogramming is a fascinating scientific goal that will shed light on the mechanisms controlling cell identity maintenance. Our laboratory studies the natural identity switch (or transdifferentiation, TD) of an epithelial rectal cell (called Y) into a motor neuron (called PDA) in Caenorhabditis elegans. In worm mutants for the gene lin-15A (isolated in a genetic screen performed in the laboratory), the Y cell does not initiate the Y reprogramming : Y stays rectal. This protein appears in the Y nucleus just before the beginning of the Y TD and plays a key role in the process initiation. LIN-15A binds DNA and its zinc finger domain (THAP-like) is essential for the initiation of Y reprogramming. Inactivation of some genes that are involved in cell identity maintenance allow a partial or strong suppression of the Y reprogramming defect due to lin-15A mutation. These genes belong to a group called synMuv B and those inducing the strongest lin- 15A phenotype suppression are all linked to the retinoblastoma (RB) pathway. In the literature, all the mutants that are PDA defect suppressors in lin-15A mutant show a switch of intestinal cell identity. Some mutants in starvation–response genes in worms show a loss of intestinal cell identity maintenance very similar to the one observed in synMuv B mutants. Interestingly, we observed that starvation (in 1st larval stage or dauer stage) induces a strong drop of the PDA defect in lin-15A mutant. Different studies suggest diapause induced by starvation trigger a loss of somatic cell identity maintenance (and possibly in intestinal cells), that could allow Y to start the reprogramming despite the lack of lin-15A, even it is a key factor to release a break and initiate the TD. In summary, my results show the cell transdifferentiation depends on a molecular key, LIN-15A, that is needed, just priorto TD initiation, to release a cell maintenance lock to allow a cell to undergo cell identity switch. My work opens the possibility that the worm physiologic and metabolic state influences cell identity maintenance. In the future, how this state is perceived has to be determined, in which cells and how this information is transmitted to Y to finally influence its plasticity.

Philosophiae Doctor - PhD / The aim of this thesis was to investigate the cellular role of the mouse RBBP6 gene using the interference RNA (RNAi) gene targeting technology and also to understand the relevance of two promoters for the RBBP6 gene. / South Africa

Philosophiae Doctor - PhD / Retinoblastoma binding protein 6 (RBBP6) is a 250 kDa protein that is implicated in mRNA processing and ubiquitination functions and has been shown to be highly up-regulated in a number of cancers. In humans and mice,RBBP6 interacts with both tumour suppressors p53 and pRb, suggesting that it is involved in regulation of transcription, induction of apoptosis and cell cycle control. Knock-out of an RBBP6 homologue PACT resulted in p53 dependent cell cycle arrest and apoptosis. Although the biological functions of RBBP6 remain largely unclear, it is possible that its functions are mediated through interaction with other cellular proteins. Since it is possible to unveil novel functions of a target protein through identifying its interacting protein partners,this study aims to further characterize the functions of RBBP6 through identifying novel protein interacting partners using a yeast 2-hybrid screen.In order to identify interaction partners of RBBP6, two well characterized domains of RBBP6, the N-terminal ubiquitin-like DWNN domain and RING finger domain, were used as baits in a yeast 2-hybrid screen of a human testis cDNA library. Putative interactors were verified using in vitro and in vivo immunoprecipitation assays. The RING finger domain was shown to interact with transcriptional factors Y-Box binding protein 1 (YB-1) and zinc finger and BTB containing protein 38 (zBTB38), resulting in their ubiquitination. In the case of YB-1 ubiquitination was correlated with a decrease in the intra-cellular levels of YB-1, suggesting that ubiquitination leads to degradation in the proteosome. The DWNN domain was shown to interact with a splicing associated small nuclear ribonucleoprotein polypeptide G (snRPG) and heat shock protein 70 (Hsp70).The results of this work suggest that, at least in the case of YB-1 and zBTB38,RBBP6 plays a role in the regulation of gene expression by ubiquitination of transcription factors, causing them to be degraded in the proteosome. The study provides further evidence of RBBP6’s involvement in mRNA splicing through its interaction with snRPG. The interaction with Hsp70 suggests a possible role in protein quality control similar to that played by other E3 ligases such as Parkin and CHIP.

Philosophiae Doctor - PhD / Retinoblastoma binding protein 6 (RBBP6) is a 250 kDa protein that is implicated in mRNA processing and ubiquitination functions and has been shown to be highly up-regulated in a number of cancers. In humans and mice, RBBP6 interacts with both tumour suppressors p53 and pRb, suggesting that it is involved in regulation of transcription, induction of apoptosis and cell cycle control. Knock-out of an RBBP6 homologue PACT resulted in p53 dependent cell cycle arrest and apoptosis. Although the biological functions of RBBP6 remain largely unclear, it is possible that its functions are mediated through interaction with other cellular proteins. Since it is possible to unveil novel functions of a target protein through identifying its interacting protein partners, this study aims to further characterize the functions of RBBP6 through identifying novel protein interacting partners using a yeast 2-hybrid screen. In order to identify interaction partners of RBBP6, two well characterized domains of RBBP6, the N-terminal ubiquitin-like DWNN domain and RING finger domain, were used as baits in a yeast 2-hybrid screen of a human testis cDNA library. Putative interactors were verified using in vitro and in vivo immunoprecipitation assays. The RING finger domain was shown to interact with transcriptional factors V-Box binding protein 1 (YB-1) and zinc finger and BTB containing protein 38 (zBTB38), resulting in their ubiquitination. In the case of YB-1 ubiquitination was correlated with a decrease in the intra-cellular levels of YB-1, suggesting that ubiquitination leads to degradation in the proteosome. The DWNN domain was shown to interact with a splicing associated small nuclear ribonucleoprotein polypeptide G (snRPG) and heat shock protein 70 (Hsp70). The results of this work suggest that, at least in the case of YB-1 and zBTB38, RBBP6 plays a role in the regulation of gene expression by ubiquitination of transcription factors, causing them to be degraded in the proteosome. The study provides further evidence of RBBP6's involvement in mRNA splicing through its interaction with snRPG. The interaction with Hsp70 suggests a possible role in protein quality control similar to that played by other E3 ligases such as Parkin and CHIP.

Photodynamic therapy (PDT) has shown to be a promising technique to treat various forms of malignant neoplasia. The photodynamic eradication of the tumor cells is achieved by applying a photosensitizer either locally or systemically and following local activation through irradiation of the tumor mass with light of a specific wavelength after a certain time of incubation. Due to preferential accumulation of the photosensitizer in tumor cells, this procedure allows a selective inactivation of the malignant tumor while sparing the surrounding tissue to the greatest extent. These features and requirements make the PDT an attractive therapeutic option for the treatment of retinoblastoma, especially when surgical enucleation is a curative option. This extreme solution is still in use in case of tumours that are resistant to conventional chemotherapy or handled too late due to poor access to medical care in less advanced country. In this study we initially conducted in-vitro investigations of the new cationic water-soluble photo sensitizer tetrahydroporphyrin-tetratosylat (THPTS) regarding its photodynamic effect on human Rb-1 and Y79 retinoblastoma cells. We were able to show, that neither the incubation with THPTS without following illumination, nor the sole illumination showed a considerable effect on the proliferation of the retinoblastoma cells, whereas the incubation with THPTS combined with following illumination led to a maximal cytotoxic effect on the tumor cells. Moreover the phototoxicity was lower in normal primary cells from retinal pigmented epithelium demonstrating a higher phototoxic effect of THPTS in cancer cells than in this normal retinal cell type. The results at hand form an encouraging foundation for further in-vivo studies on the therapeutic potential of this promising photosensitizer for the eyeball and vision preserving as well as potentially curative therapy of retinoblastoma.

Le rétinoblastome est un cancer pédiatrique rare de la rétine en cours de développement. Si dans les pays développés, le taux de survie avoisine 100%, une énucléation de l’oeil atteint est cependant nécessaire dans plus de 70% des cas.En 1971, Knudson émit l’hypothèse des deux “hits”, qui permit de comprendre que le rétinoblastome s’initie généralement après une perte bi-allélique du gène RB1. Cependant, les autres mécanismes moléculaires qui régissent ce cancer restent depuis peu connus. Par exemple, peu d’études génomiques ont été conduites. Ainsi, la nature de la cellule d’origine, ainsi que la présence ou non d’une hétérogénéité intertumorale, font encore débat. Dans cette étude, nous avons dressé un portrait génomique et clinique complet du rétinoblastome; plusieurs observations ont montré qu’il s’agit bien d’une maladie hétérogène, avec deux sous-types distincts. Nous avons d’abord identifié les deux sous-types avec à une approche couplant une analyse en composantes indépendantes (ACI) de transcriptomes tumoraux avec des marquages immunohistochimiques. Les rétinoblastomes du premier sous-type, dits “cone-like” expriment uniformément des marqueurs de cônes, tandis que ceux du second sous-type, dits “bivalent-type”, ont une forte hétérogénéité intratumorale, avec un enchevêtrement de zones de différenciation ganglionnaire ou cône. Grâce à une étude plus approfondie des transcriptomes et de données d’altérations génomiques, nous avons ensuite montré que les sous-types dépendent de voies de signalisation et d’oncogènes différents. Les bivalent-type ont notamment une présence quasi-systématique de gains de MDM4 ou d’amplifications de MYCN. Nous nous sommes ensuite tournés vers les méthylomes des rétinoblastomes, et constaté une forte hétérogénéité entre les sous-types. Nous avons décomposé cette hétérogénéité grâce à une ACI, et constaté qu’elle n’était pas liée uniquement à la différenciation cône ou ganglion. Nous avons ensuite étudié les données cliniques de la cohorte, et constaté que les sous-types avaient des âges au diagnostic et des formes de croissance différents, les tumeurs cone-like se developpant généralement chez des patients jeunes avec des tumeurs exophytiques, et les bivalent-type chez des patients plus âgés avec des tumeurs endophytiques. De plus, les patients avec des inactivations constitutionnelles du gène RB1 développent majoritairement des tumeurs cone-like; les cone-like s’initieraient donc plus tôt durant le développement de la rétine. Nous avons finalement séquencé les exomes de 74 paires tumeur-normal. Les rétinoblastomes avaient un taux de mutations extrêmement faible (0.1 mutations par mégabase), comme beaucoup de cancers pédiatriques. Nous avons identifié des mutations somatiques récurrentes dans RB1, BCOR et ARID1A. Ces gènes se trouvaient de plus dans des régions minimales de pertes chromosomiques. Surtout, les inactivations des deux gènes avaient souvent de fortes fréquences alléliques. Ceci indique que ces inactivations ont lieu précocément dans la tumorigénèse. En conclusion, notre étude a permis de dresser un premier portrait génomique complet du rétinoblastome, a révélé l’existence de deux sous-types distincts, ainsi que fourni des indices quant à la cellule d’origine de chaque sous-type, et les mécanismes moléculaires les régissant. / Retinoblastoma is a rare pediatric cancer of the developing retina. In high-income countries, survival rates near 100%; however, enucleation of the affected eye has to be performed in over 70% of patients. Knudson’s 1971 two-hit hypothesis led to the discovery that this cancer usually initiates after a bi-allelic loss of the RB1 gene. Despite this early finding, little is known about the other molecular underpinnings of retinoblastoma. For instance, few genome-wide studies have described the genetic and epigenetic characteristics of these tumors. Furthermore, there is still no clear consensus regarding this cancer’s cell of origin, or whether or not it is homogenous disease. In this study, we built a comprehensive molecular and clinical portrait of retinoblastoma. Several lines of evidence led us to conclude that retinoblastoma is in fact a heterogeneous disease, with two distinct subtypes. We first uncovered the subtypes through a strategy that coupled an independent component analysis (ICA) of tumor transcriptomes to tumor immunohistochemical stainings. Retinoblastomas of the first subtype, called “cone-like”, homogeneously display cone-like differentiation, while those of the second subtype, called “bivalent-type”, exhibit strong intratumoral heterogeneity, with areas of cone-like differentiation intertwined with areas of ganglion-like differentiation. Further analysis of the transcriptomic data, as well as of copy number alteration data revealed that both subtypes may rely on different pathways and oncogenes. We notably observed a quasi-systematic presence of MDM4 gains or MYCN amplifications in bivalent-type tumors. We next turned to retinoblastomas’ methylomes; these considerably varied between the subtypes. ICA allowed us to decompose this inter-subtype methylomic heterogeneity, which was found to go beyond methylation due to cone-like or ganglion-like differentiation. We next studied the tumors’ clinical data, and found that cone-like tumors are most often diagnosed in very young patients with exophytic tumor growth, while bivalent-type tumors are found in older patients with endophytic tumor growth. Furthermore, patients with germline inactivations of RB1 mostly developed cone-like retinoblastomas, indicating that these tumors may initiate earlier during retinal development. In the final part of our study, we performed whole exome sequencing of 74 tumor-normal pairs. Like many pediatric cancers, the tumors had very low background mutation rates (0.1 mutations per megabase). Recurrent somatic mutations were found in RB1, BCOR and ARID1A, and these genes were also found to be in minimal regions of chromosomal losses. Importantly, both inactivations often had very high allelic frequencies, indicating that these events occur very early on in retinoblastoma tumorigenesis.Taken together, our study outlines a first comprehensive genomic portrait of retinoblastomas, points to the existence of two distinct subtypes, and provides insights into the cells-or-origin and the molecular mechanisms underlying these subtypes.

L'avancée technologique dans les nanosciences a permis le développement d'une large gamme de matériaux nanostructurés aux applications biomédicales. Ces outils, constitués de matériaux différents, ont été développés à des fins de diagnostic et de thérapie pour réaliser notamment le ciblage, le marquage cellulaire, l'imagerie médicale et pour concevoir des systèmes de délivrance de médicaments pour le traitement de cancers ou de maladies infectieuses. La création de nano-objets regroupant l'ensemble de ces propriétés de type théranostique constitue une étape essentielle vers un traitement personnalisé et non invasif des cancers solides de petite taille. Dans cette thèse, une première partie est consacrée à la mise au point et à l'utilisation de nanoparticules de silice mésoporeuse pour le traitement des rétinoblastomes. Ce travail visait à améliorer la thérapie photodynamique en augmentant la biodisponibilité de molécules actives dans les cellules cancéreuses par deux stratégies : leur vectorisation par un nano-objet et le ciblage spécifique des cellules cancéreuses. Pour cela, les profils d'expression des récepteurs du mannose ont été analysés et les récepteurs MRC2 et CD209 se sont révélés être de bons candidats pour une thérapie ciblée du rétinoblastome. La deuxième partie des recherches réalisées s'oriente vers l'élaboration de différents nanosystèmes pour le traitement des cancers et l'imagerie médicale. Premièrement, des nanotransporteurs de principe actif à relargage pH-sensible, structurés à partir de nanoparticule de silice mésoporeuse, ont été étudiés. Ces systèmes de délivrance, sous l'effet de stimuli internes, se sont révélés être très efficaces in vitro et ex vivo pour le traitement du cancer du côlon. Deuxièmement, le potentiel de délivrance contrôlée de molécules anticancéreuses renfermées dans des nanomachines soumises à une activation externe biphotonique, a été démontré sur des cellules de cancer du sein. Enfin, les propriétés de nanoparticules magnétiques de polymères de coordination cyano-pontés se sont révélées très prometteuses pour une utilisation en tant que nouvel agent de contraste intravasculaire pour l'imagerie par résonance magnétique in vivo. / The technological advance in nanoscience has allowed the development of a wide range of nanostructured materials for biomedical applications. These tools, composed of different materials, have been developed for diagnosis and therapy, in particular to achieve targeting, cellular labeling, medical imaging and to design drug delivery systems for the treatment of cancer or infectious diseases. The elaboration of nano-tools possessing these theranostic properties would be a major step towards personalized and non-invasive treatments of small solid cancers.In this thesis, the first part is devoted to the development and the application of mesoporous silica nanoparticles for the treatment of retinoblastoma. The aim of this work was to improve photodynamic therapy by increasing the bioavailability of active molecules in cancer cells following two strategies: their vectorization through nanodevice and the specific targeting of cancer cells. For this, expression profiles of mannose receptors were analyzed and both MRC2 and CD209 receptors were found to be interesting candidates for targeted therapy of retinoblastoma.The second part corresponds to a multidisciplinary approach focused on the research of different nanosystems designed for cancer treatment and medical imaging. We first studied pH-operated hybrid silica nanocarriers designed for drug release. Under internal stimuli, these delivery systems have shown to be very efficient in vitro and ex vivo against colon cancer. Then, we demonstrated the potential of nanoimpellers designed for anticancer drug delivery mediated by external two-photon activation on breast cancer cells. Finally, we report the promising use in vivo of new magnetic cyano-bridged coordination polymer nanoparticles as an efficient intravascular magnetic resonance imaging contrast agent.